ERYTECH announces the enrollment of the first patient in its Phase II study with eryaspase in second line treatment of patients affected by pancreatic cancer.
ERYTECH announces the enrollment of the first patient in its Phase II study with eryaspase in second line treatment of patients affected by pancreatic cancer.